THC Stock Analysis: Tenet Healthcare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 20.812m USD | 12M Return: 41.5% | US88033G4073 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 161M
EPS Trend: 98.4%
Qual. Beats: 3
Rev. Trend: 78.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tenet Healthcare Corporation (NYSE: THC) is a U.S.-based diversified healthcare services company headquartered in Dallas, Texas, operating through two main segments: Hospital Operations and Services, and Ambulatory Care. Founded in 1967, the company runs a large network of general acute care hospitals offering a broad range of services, including emergency and trauma care, intensive and critical care, specialty surgery, and transplant programs. Its facilities also provide diagnostic and outpatient services such as radiology, laboratory work, pharmacy, physical therapy, and various procedural specialties including orthopedics, gastroenterology, and pain management.
In addition to its inpatient operations, Tenet has expanded into outpatient and ambulatory settings, operating surgical hospitals, ambulatory surgery centers, urgent care centers, imaging centers, off-campus emergency departments, and micro-hospitals. The company also invests in advanced clinical capabilities such as surgical robotics, minimally invasive cardiac procedures, intravascular stroke care, and telemedicine access. As a large-cap participant in the Health Care Facilities sub-industry, Tenet competes with other major for-profit hospital operators that pursue a similar strategy of combining acute inpatient care with higher-margin outpatient and ambulatory services to diversify revenue streams.
- USPI ambulatory surgery centers drive high-margin revenue growth
- Hospital labor costs pressure operating margins amid wage inflation
- Capital allocation prioritizes debt reduction and share repurchases
| Net Income: 2.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.41 > 1.0 |
| NWC/Revenue: 10.36% < 20% (prev 14.63%; Δ -4.27% < -1%) |
| CFO/TA 0.13 > 3% & CFO 4.01b > Net Income 2.24b |
| Net Debt (11.1b) to EBITDA (5.06b): 2.19 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.0m) vs 12m ago -8.53% < -2% |
| Gross Margin: 26.87% > 18% (prev 61.49%; Δ -34.63% > 0.5%) |
| Asset Turnover: 73.47% > 50% (prev 72.09%; Δ 1.39% > 0%) |
| Interest Coverage Ratio: 5.08 > 6 (EBIT TTM 4.17b / Interest Expense TTM 820.0m) |
| A: 0.07 (Total Current Assets 7.83b - Total Current Liabilities 5.57b) / Total Assets 30.7b |
| B: 0.19 (Retained Earnings 5.94b / Total Assets 30.7b) |
| C: 0.14 (EBIT TTM 4.17b / Avg Total Assets 29.7b) |
| D: 0.21 (Book Value of Equity 4.66b / Total Liabilities 22.0b) |
| Altman-Z'' = 2.28 = BBB |
| DSRI: 0.67 (Receivables 2.61b/3.70b, Revenue 21.8b/20.7b) |
| GMI: 2.29 (GM 61.49% / 26.87%) |
| AQI: 1.01 (AQ_t 0.54 / AQ_t-1 0.54) |
| SGI: 1.05 (Revenue 21.8b / 20.7b) |
| TATA: -0.06 (NI 2.24b - CFO 4.01b) / TA 30.7b) |
| Beneish M = -2.09 (Cap -4..+1) = BB |
As of October 13, 2026, the stock is trading at USD 268.76 with a total of 509,100 shares traded. Over the past week, the price has changed by +3.58%, over one month by +1.61%, over three months by +37.96% and over the past year by +41.45%.
Current recommended Stop Loss: 259.20 (which is 3.6% or 1.3 ATR below the current price).
Tenet Healthcare has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy THC.
- StrongBuy: 14
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 284.6 | 5.9% |
P/E Trailing = 9.9526
P/E Forward = 12.5313
P/S = 0.9541
P/B = 4.53
P/EG = 1.8172
Revenue TTM = 21.8b USD
EBIT TTM = 4.17b USD
EBITDA TTM = 5.06b USD
Long Term Debt = 13.1b USD (from longTermDebt, last quarter)
Short Term Debt = 160.0m USD (from shortTermDebt, last quarter)
Debt = 13.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.1b USD (calculated: Debt 13.2b - CCE 2.17b)
Enterprise Value = 31.9b USD (20.8b + Debt 13.2b - CCE 2.17b)
Interest Coverage Ratio = 5.08 (Ebit TTM 4.17b / Interest Expense TTM 820.0m)
EV/FCF = 10.55x (Enterprise Value 31.9b / FCF TTM 3.02b)
FCF Yield = 9.48% (FCF TTM 3.02b / Enterprise Value 31.9b)
FCF Margin = 13.86% (FCF TTM 3.02b / Revenue TTM 21.8b)
Net Margin = 10.27% (Net Income TTM 2.24b / Revenue TTM 21.8b)
Gross Margin = 26.87% ((Revenue TTM 21.8b - Cost of Revenue TTM 16.0b) / Revenue TTM)
Gross Margin QoQ = 18.19% (prev 16.43%)
Tobins Q-Ratio = 1.04 (Enterprise Value 31.9b / Total Assets 30.7b)
Interest Expense / Debt = 6.19% (Interest Expense 820.0m / Debt 13.2b)
Taxrate = 17.88% (691.0m / 3.87b)
NOPAT = 3.42b (EBIT 4.17b * (1 - 17.88%))
Current Ratio = 1.41 (Total Current Assets 7.83b / Total Current Liabilities 5.57b)
Debt / Equity = 2.84 (Debt 13.2b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.19 (Net Debt 11.1b / EBITDA 5.06b)
Debt / FCF = 3.66 (Net Debt 11.1b / FCF TTM 3.02b)
Total Stockholder Equity = 4.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.55% (Net Income 2.24b / Total Assets 30.7b)
RoE = 50.63% (Net Income TTM 2.24b / Total Stockholder Equity 4.43b)
RoCE = 23.78% (EBIT 4.17b / Capital Employed (Equity 4.43b + L.T.Debt 13.1b))
RoIC = 14.15% (NOPAT 3.42b / Invested Capital 24.2b)
WACC = 7.51% (E(20.8b)/V(34.1b) * Re(9.06%) + D(13.2b)/V(34.1b) * Rd(6.19%) * (1-Tc(0.18)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.75 | Cagr: -7.72%
[DCF] Terminal Value 77.97% ; FCFF base≈2.44b ; Y1≈2.80b ; Y5≈4.11b
[DCF] Fair Price = 631.4 (EV 61.9b - Net Debt 11.1b = Equity 50.8b / Shares 80.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.43 | EPS CAGR: 48.74% | SUE: 4.0 | # QB: 3
Revenue Correlation: 78.18 | Revenue CAGR: 1.88% | SUE: 2.42 | # QB: 1
EPS current Quarter (2026-09-30): EPS=4.67 | Chg30d=+0.03% | Revisions=+0% | Analysts=20
EPS current Year (2026-12-31): EPS=21.22 | Chg30d=-0.00% | Revisions=+0% | GrowthEPS=+26.5% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=21.08 | Chg30d=+0.01% | Revisions=+38% | GrowthEPS=-0.7% | GrowthRev=+0.4%
[Analyst] Revisions Ratio: +25% (up=6, down=3)